Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025)
Legend Biotech (LEGN) posted Net Income towards Common Stockholders of -$30.9 million for Q4 2025, up 19.65% on a QoQ basis from -$38.5 million in Q3 2025, and up 47.7% year-over-year from -$20.9 million in Q4 2024.
Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Legend Biotech's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$30.9 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 47.7% year-over-year to -$30.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$294.5 million (down 12.23% YoY) and the FY2025 annual result came in at -$296.8 million, down 57.19% from the prior year.
- Net Income towards Common Stockholders was -$30.9 million for Q4 2025 at Legend Biotech, up from -$38.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $172.6 million in Q2 2021 and bottomed at -$199.1 million in Q2 2023.
- A 5-year average of -$75.3 million and a median of -$86.6 million in 2021 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders surged 227.95% — and 2022, when it sank 35570.18%.
- Legend Biotech's Net Income towards Common Stockholders stood at -$88.3 million in 2021, then tumbled by 53.82% to -$135.9 million in 2022, then soared by 34.83% to -$88.5 million in 2023, then soared by 33.27% to -$59.1 million in 2024, then jumped by 47.7% to -$30.9 million in 2025.
- Business Quant data shows LEGN's Net Income towards Common Stockholders at -$30.9 million in Q4 2025, -$38.5 million in Q3 2025, and -$124.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | -30.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.90 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -100.92 Mn |
| Dec 31, 2024 | -59.08 Mn |
| Sep 30, 2024 | -125.32 Mn |
| Jun 30, 2024 | -18.20 Mn |
| Mar 31, 2024 | -59.79 Mn |
| Dec 31, 2023 | -88.55 Mn |
| Sep 30, 2023 | -62.21 Mn |
| Jun 30, 2023 | -199.13 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -135.88 Mn |
| Sep 30, 2022 | -84.96 Mn |
| Jun 30, 2022 | -193.23 Mn |
| Mar 31, 2022 | -32.29 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | 172.57 Mn |
| Mar 31, 2021 | -90,521.00 |